Phase 1Completed

Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)

Comparative Randomized, Single Dose, Three-way, Three-sequence, Two Treatment, Partial Replicate, Crossover, Open-label Study to Determine the Bioequivalence of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)

Sponsor

Genuine Research Center, Egypt (Industry)

Enrollment

28 enrolled

Conditions

Healthy

Interventions

Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose); Nirmatrelvir 150 mg + Ritonavir 100 mg (test); Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)

Ages

adults

Registry

NCT05491330

Full record on ClinicalTrials.gov